426 related articles for article (PubMed ID: 28895886)
21. [Non-melanoma skin cancers and human papillomavirus].
Aubin F; Humbey O; Guérrini JS; Mougin C; Laurent R
Ann Dermatol Venereol; 2003 Dec; 130(12 Pt 1):1131-8. PubMed ID: 14724516
[TBL] [Abstract][Full Text] [Related]
22. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection.
Clerici M; Merola M; Ferrario E; Trabattoni D; Villa ML; Stefanon B; Venzon DJ; Shearer GM; De Palo G; Clerici E
J Natl Cancer Inst; 1997 Feb; 89(3):245-50. PubMed ID: 9017005
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
24. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV
Galliverti G; Wullschleger S; Tichet M; Murugan D; Zangger N; Horton W; Korman AJ; Coussens LM; Swartz MA; Hanahan D
Cancer Immunol Res; 2020 Jan; 8(1):131-145. PubMed ID: 31771984
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus infections in skin cancers.
de Villiers EM
Biomed Pharmacother; 1998; 52(1):26-33. PubMed ID: 9755792
[TBL] [Abstract][Full Text] [Related]
26. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review.
Cobos C; Figueroa JA; Mirandola L; Colombo M; Summers G; Figueroa A; Aulakh A; Konala V; Verma R; Riaz J; Wade R; Saadeh C; Rahman RL; Pandey A; Radhi S; Nguyen DD; Jenkins M; Chiriva-Internati M; Cobos E
Int Rev Immunol; 2014 Oct; 33(5):383-401. PubMed ID: 24811210
[TBL] [Abstract][Full Text] [Related]
27. Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers.
Zhang L; Zhou F; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):512-521. PubMed ID: 27993116
[TBL] [Abstract][Full Text] [Related]
28. [Papillomavirus infections and cervical tumorigenesis].
Kiyono T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):227-31. PubMed ID: 20235389
[No Abstract] [Full Text] [Related]
29. Immune deviation and cervical carcinogenesis.
Smola S
Papillomavirus Res; 2019 Jun; 7():164-167. PubMed ID: 30980967
[TBL] [Abstract][Full Text] [Related]
30. Cervical dysplasia in a patient with inherited epidermodysplasia verruciformis-A mere coincidence?
Singh AP; Jeffus SK; Shalin SC
J Cutan Pathol; 2021 Jun; 48(6):763-770. PubMed ID: 33319409
[TBL] [Abstract][Full Text] [Related]
31. NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy.
Gutiérrez-Hoya A; Soto-Cruz I
Cells; 2021 Nov; 10(11):. PubMed ID: 34831327
[TBL] [Abstract][Full Text] [Related]
32. Human Papillomavirus Infection and p16 Expression in Extragenital/Extraungual Bowen Disease in Immunocompromised Patients.
Švajdler M; Mezencev R; Kašpírková J; Kacerovská D; Kazakov DV; Ondič O; Michal M
Am J Dermatopathol; 2016 Oct; 38(10):751-7. PubMed ID: 26913849
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
Yang W; Song Y; Lu YL; Sun JZ; Wang HW
Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
[TBL] [Abstract][Full Text] [Related]
34. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
[TBL] [Abstract][Full Text] [Related]
35. Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix.
Machado FA; Janssens JP; Michelin MA; Murta EF
Clin Exp Obstet Gynecol; 2012; 39(1):27-31. PubMed ID: 22675951
[TBL] [Abstract][Full Text] [Related]
36. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
37. IMMUNOLOGY OF CERVICAL CANCER.
Manzo-Merino J; Del-Toro-Arreola S; Rocha-Zavaleta L; Peralta-Zaragoza Ó; Jiménez-Lima R; Madrid-Marina V
Rev Invest Clin; 2020; 72(4):188-197. PubMed ID: 33064686
[TBL] [Abstract][Full Text] [Related]
38. HPV Infection-Associated Cancers: Next-Generation Technology for Diagnosis and Treatment.
Trimble CL
Cancer Immunol Res; 2014 Oct; 2(10):937-42. PubMed ID: 25281321
[TBL] [Abstract][Full Text] [Related]
39. APOBEC-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis.
Chen L; Qiu X; Zhang N; Wang Y; Wang M; Li D; Wang L; Du Y
Biosci Trends; 2017 Sep; 11(4):383-388. PubMed ID: 28717061
[TBL] [Abstract][Full Text] [Related]
40. Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.
Barros MR; de Oliveira THA; de Melo CML; Venuti A; de Freitas AC
J Immunol Res; 2018; 2018():2912671. PubMed ID: 29854832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
